Definely has secured a £585,000 grant from Innovate UK, as part of a broader funding landscape where the first group of participants closed over £10 million in funding from private investors and grants. This follows a total of nearly £20 million in commitments being finalized. In a significant development in the biotech sector, Healx, a Cambridge-based AI-enabled drug discovery platform specializing in treatments for rare diseases, announced it has raised $47 million in a Series C financing round. The funding was co-led by Atomico and R42 Group. Additionally, Healx has received FDA clearance for its Phase 2 IND trial targeting Neurofibromatosis Type 1.